---
title: 'Autogene cevumeran with or without atezolizumab in advanced solid tumors:
  a phase 1 trial'
date: '2025-01-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39762422/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250107170841&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Effective targeting of somatic cancer mutations to enhance the efficacy
  of cancer immunotherapy requires an individualized approach. Autogene cevumeran
  is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy
  designed from tumor-specific somatic mutation data obtained from tumor tissue of
  each individual patient to stimulate T cell responses against up to 20 neoantigens.
  This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30)
  and ...
disable_comments: true
---
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and ...